Cost utility analysis of the SQ® HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting

Table 2 Summary of cost and resource use inputs incorporated in the analysis

Resource	Unit price	Annual resource use		Total cost
Resource	Unit price	ACARIZAX	Pharmacotherapy	ACARIZAX	Pharmacotherapy
ACARIZAX tablet^a	€2.53	365	0	€923	€0
GP visits^b	€29.35	0.175	0.105	€5.13	€3.07
Emergency room visits^b	€74.96	0.010	0.025	€0.75	€1.89
ICS daily dose (μg)^c	€18.14	563	555	€373	€363
SABA intake (doses)^c	€22.15	266	297	€9.82	€10.96

Three drugs and two other medical resources were included as parameters in the analysis. Resource use was based on data recorded in MT-04 and, therefore, they relate specifically to allergic asthma patients. The values have been multiplied by the unit price of each resource to generate total costs. These costs were applied to a one year period, and applied equally across all years in the analysis (with costs also discounted at 3 % per year in line with German guidelines)
^aSource: http://www2.lauer-fischer.de/
^bSource: http://www.kbv.de/html/
^cSource: https://www.gkv-spitzenverband.de

ISSN: 2045-7022